Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
Richardson SI, Mzindle N, Motlou T, Manamela NP, van der Mescht MA, Lambson BE, Everatt J, Amoako DG, Balla S, von Gottberg A, Wolter N, de Beer Z, de Villiers TR, Bodenstein A, van den Berg G, Abdullah F, Rossouw TM, Boswell MT, Ueckermann V, Bhiman JN, Moore PL. Richardson SI, et al. Among authors: motlou t. J Virol. 2024 Jul 23;98(7):e0067824. doi: 10.1128/jvi.00678-24. Epub 2024 Jul 2. J Virol. 2024. PMID: 38953380 Free article.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Le Roux J, Lustig G, Madzivhandila M, Magugu SFJ, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. Among authors: motlou tp. PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38603677 Free PMC article.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Roux JL, Lustig G, Madzivhandila M, Magugu SF, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. Among authors: motlou tp. medRxiv [Preprint]. 2023 Nov 20:2023.11.20.23298785. doi: 10.1101/2023.11.20.23298785. medRxiv. 2023. Update in: PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703 PMID: 38045321 Free PMC article. Updated. Preprint.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: motlou t. PLoS Pathog. 2023 Nov 9;19(11):e1011772. doi: 10.1371/journal.ppat.1011772. eCollection 2023 Nov. PLoS Pathog. 2023. PMID: 37943890 Free PMC article.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: motlou t. medRxiv [Preprint]. 2023 Mar 15:2023.03.15.23287288. doi: 10.1101/2023.03.15.23287288. medRxiv. 2023. Update in: PLoS Pathog. 2023 Nov 9;19(11):e1011772. doi: 10.1371/journal.ppat.1011772 PMID: 36993404 Free PMC article. Updated. Preprint.
Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
O'Kennedy MM, Abolnik C, Smith T, Motlou T, Goosen K, Sepotokele KM, Roth R, du Preez I, Truyts A, Stark HC, Magwaza M, Mahanjana O, Verschoor JA, Moore PL, Lemmer Y. O'Kennedy MM, et al. Among authors: motlou t. Vaccine. 2023 Mar 24;41(13):2261-2269. doi: 10.1016/j.vaccine.2023.02.050. Epub 2023 Feb 27. Vaccine. 2023. PMID: 36868876 Free PMC article.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA, Kwatra G, Richardson SI, Koen AL, Baillie V, Cutland CL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Ahmed K, Aley PK, Bhikha S, Bhorat AE, Esmail A, Horne E, Kaldine H, Mukendi CK, Madzorera VS, Manamela NP, Masilela M, Hermanus ST, Motlou T, Mzindle N, Oelofse S, Patel F, Rhead S, Rossouw L, Taoushanis C, van Eck S, Lambe T, Gilbert SC, Pollard AJ, Moore PL, Izu A. Madhi SA, et al. Among authors: motlou t. Lancet Infect Dis. 2023 Mar;23(3):295-306. doi: 10.1016/S1473-3099(22)00596-5. Epub 2022 Oct 20. Lancet Infect Dis. 2023. PMID: 36273491 Free PMC article. Clinical Trial.
Augmenting glycosylation-directed folding pathways enhances the fidelity of HIV Env immunogen production in plants.
Margolin E, Allen JD, Verbeek M, Chapman R, Meyers A, van Diepen M, Ximba P, Motlou T, Moore PL, Woodward J, Strasser R, Crispin M, Williamson AL, Rybicki EP. Margolin E, et al. Among authors: motlou t. Biotechnol Bioeng. 2022 Oct;119(10):2919-2937. doi: 10.1002/bit.28169. Epub 2022 Jul 19. Biotechnol Bioeng. 2022. PMID: 35781691 Free PMC article.
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
Kitchin D, Richardson SI, van der Mescht MA, Motlou T, Mzindle N, Moyo-Gwete T, Makhado Z, Ayres F, Manamela NP, Spencer H, Lambson B, Oosthuysen B, Kaldine H, du Pisanie M, Mennen M, Skelem S, Williams N, Ntusi NAB, Burgers WA, Gray GG, Bekker LG, Boswell MT, Rossouw TM, Ueckermann V, Moore PL. Kitchin D, et al. Among authors: motlou t. Cell Rep Med. 2022 Feb 10;3(3):100535. doi: 10.1016/j.xcrm.2022.100535. eCollection 2022 Mar 15. Cell Rep Med. 2022. PMID: 35474744 Free PMC article.
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.
Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht MA, Lambson BE, Oosthuysen B, Ayres F, Makhado Z, Moyo-Gwete T, Mzindle N, Motlou T, Strydom A, Mendes A, Tegally H, de Beer Z, Roma de Villiers T, Bodenstein A, van den Berg G, Venter M, de Oliviera T, Ueckermann V, Rossouw TM, Boswell MT, Moore PL. Richardson SI, et al. Among authors: motlou t. Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4. doi: 10.1016/j.chom.2022.03.029. Epub 2022 Mar 25. Cell Host Microbe. 2022. PMID: 35436444 Free PMC article.
16 results